June 18, 2014—The Health Resources and Services Administration announced this morning that it stands by its interpretation of the 340B orphan drug exclusion that lets critical access hospitals, sole community hospitals, rural referral centers, and free-standing cancer hospitals access 340B pricing on orphan drugs when they “are used for any indication other than treating the rare disease or condition for which the drug received an orphan designation.”
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)